Conmed Sees FY2026 Adj EPS $4.48-$4.60 vs $4.34 Est; Narrows FY2026 Sales Guidance from $1.350B-$1.375B to $1.358B-$1.373B vs $1.362B Est
Conmed (NYSE:CNMD) is looking for FY2026 Adj EPS of $4.48-$4.60 vs $4.34 analyst estimate. Narrows FY2026 sales outlook from $1.350 billion-$1.375 billion to $1.358 billion-$1.373 billion vs $1.362 billion estimate.
Conmed says it will make more money per share than experts thought, but its total sales will be about the same as expected. When a company beats on profits but keeps sales flat, it usually means they're running their business more efficiently.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.